Interesting to look back at the release re the two patents for PTX-200. Your supposition that our CellPryme Adjuvant is based on the targeted therapy tech of PTX-200 is correctomundo. So it could form part of the personalised therapy to be incorporated into our flagship CarT clinical trial for AML next year (not as a targeted therapy as our trial in AML is currently) but as an Adjuvant.
As you state, "I’m happy to see the company very cleverly working to derive maximum value from an existing asset"... I agree. It seems, however, that the second patent for PTX-200 is being utilised in the manner in which it was originally intended. Things are coming together, and whilst there are going to be different and stand-alone breakthroughs being made in the next-gen CarT therapy space, the potential reach that OmniCAR and CellPryme (with its personalised plug-and-play approach) across a very broad spectrum should not be underestimated.
